Polygenic Risk Scoring With Geo-Ethnic PCs for Type 2 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing clinical prediction models for cardiovascular and renal complications in type 2 diabetes have limitations in predictive accuracy and do not effectively account for genetic factors, necessitating improved methods for early risk prediction and therapeutic response.
Innovation Solution
Development of a polygenic risk score (PRS) combining genetic variants with clinical risk factors, incorporating a geo-ethnic principal component, to predict disease complications and response to therapy in type 2 diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional clinical prediction models are used, then the models are simple to implement, but the predictive accuracy is insufficient
Solution Approach 1:
The patent combines multiple genetic variants (hundreds or thousands of SNPs) into a unified polygenic risk score that integrates with clinical risk factors. This merging of genetic and clinical data into a single composite score improves predictive accuracy while maintaining practical usability in clinical settings.
Solution Approach 2:
The prediction model uses a composite approach by integrating diverse data types including genetic variants, clinical risk factors, and demographic information into a unified risk assessment framework. This composite model leverages the strengths of each data type to achieve superior predictive performance compared to single-source models.
2Reliability
If genetic variants are added to prediction models, then the predictive power is improved, but the computational complexity increases
Solution Approach 1:
The patent segments the genetic information into discrete, independently analyzable variants (SNPs), each with assigned effect sizes from GWAS studies. This segmentation allows for systematic processing and weighting of individual genetic factors, making the overall computation more manageable while maintaining comprehensive genetic assessment.
Solution Approach 2:
The model transforms raw genetic variant data into standardized risk scores by applying effect size weights and aggregating across multiple variants. This parameter transformation converts complex genetic information into a simplified, interpretable risk metric that can be easily integrated with clinical data and used for prediction.
3Measurement precision
If polygenic risk scores are used, then the identification of high-risk individuals is improved, but the cost of genotyping increases
Solution Approach 1:
The patent extracts only the most informative genetic variants identified through GWAS studies, focusing on a specific subset of SNPs with known associations to diabetes complications. This extraction approach avoids unnecessary genotyping of irrelevant variants, reducing costs while maintaining predictive power by concentrating resources on high-value genetic markers.
Data Source
AI summary
Methods, processes, and systems for predicting a subject's disease complications and/or response to therapy are described herein. The methods generally comprise genotyping or receiving genotyping information from the subject at a plurality of risk alleles associated with the disease and at a plurality of ancestry-informative markers. The genotyping information is used to generate a polygenic risk score (PRS) by weighting the number of risk alleles by the effect size of their association (weighted genetic risk score or wGRS), combined with a geo-ethnic principal component (PC) determined from the subject's genotype at said ancestry-informative markers. The PRS enables better prediction of the subject's disease complications and/or response to therapy, as compared to a corresponding PRS generated lacking the geo-ethnic principal component. Computer-implemented methods and processes are also described herein.